Antileukemic and Immunosuppressive Activity of 2-chloro-2'-deoxyadenosine

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1984 Apr 1

PMID 6585795

Citations 29

Authors

D A Carson

D B Wasson

E Beutler

Affiliations

Soon will be listed here.

Abstract

The adenosine deaminase-resistant purine deoxynucleoside 2-chloro-2'-deoxyadenosine (CdA) is markedly toxic in vitro to nondividing and proliferating normal human lymphocytes and to many leukemia cell specimens. The CdA is also effective against mouse L1210 leukemia in vivo. The present investigations have examined the pharmacology, chemotherapeutic activity, and toxicity of CdA in nine patients with advanced hematologic malignancies refractory to conventional therapy. When administered by continuous intravenous infusion, the deoxyadenosine analog was well tolerated. As monitored by radioimmunoassay, plasma CdA levels rose gradually during the infusions. The CdA was not deaminated significantly. In all patients with leukemia, the CdA lowered the blast count by at least 50%. In one patient with a T-cell leukemia-lymphoma, and in another patient with chronic myelogenous leukemia in blast crisis, the CdA infusion eliminated all detectable blasts from the blood and bone marrow. In a patient with a diffuse lymphoma complicated by severe autoimmune hemolytic anemia, CdA treatment quickly terminated the hemolytic process. Bone marrow suppression represented the dose-limiting toxicity, and was related to plasma CdA levels, cumulative drug dosage, and the rapid release of CdA that accompanied tumor cell lysis.

Citing Articles

2'-Fluorinated nucleoside chemistry for new drug discovery: achievements and prospects.

Meng Y, Sun N, Liang L, Yu B, Chang J Natl Sci Rev. 2024; 11(10):nwae331.

PMID: 39526027 PMC: 11546638. DOI: 10.1093/nsr/nwae331.

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.

Ali S, Raj R, Kaur T, Weadick B, Nayak D, No M Cancers (Basel). 2022; 14(13).

PMID: 35804885 PMC: 9264962. DOI: 10.3390/cancers14133113.

A Novel One-Pot Enzyme Cascade for the Biosynthesis of Cladribine Triphosphate.

Frisch J, Marsic T, Loderer C Biomolecules. 2021; 11(3).

PMID: 33668847 PMC: 7996316. DOI: 10.3390/biom11030346.

Cladribine repurposed in multiple sclerosis: making a fortune out of a generic drug.

Buiter H, Derijks L, Mulder C Eur J Hosp Pharm. 2019; 26(5):246-247.

PMID: 31656609 PMC: 6788269. DOI: 10.1136/ejhpharm-2019-002026.

Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series.

Ceesay M, Basu T, du Vivier A, Mufti G BMJ Case Rep. 2019; 12(10).

PMID: 31645386 PMC: 6827816. DOI: 10.1136/bcr-2019-232480.

References

Major P, Agarwal R, Kufe D . Clinical pharmacology of deoxycoformycin. Blood. 1981; 58(1):91-6. View

Grever M, Siaw M, Jacob W, Neidhart J, Miser J, Coleman M . The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood. 1981; 57(3):406-17. View

Hershfield M, Fetter J, Small W, Bagnara A, Williams S, Ullman B . Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem. 1982; 257(11):6380-6. View

Carson D, Wasson D, Lakow E, Kamatani N . Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci U S A. 1982; 79(12):3848-52. PMC: 346525. DOI: 10.1073/pnas.79.12.3848. View

Montgomery J . Has the well gone dry? The First Cain Memorial Award Lecture. Cancer Res. 1982; 42(10):3911-7. View

Carson D, Wasson D, Taetle R, Yu A . Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983; 62(4):737-43. View

Christensen L, BROOM A, Robins M, Bloch A . Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl)purines. J Med Chem. 1972; 15(7):735-9. DOI: 10.1021/jm00277a010. View

GIBLETT E, Anderson J, Cohen F, POLLARA B, Meuwissen H . Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972; 2(7786):1067-9. DOI: 10.1016/s0140-6736(72)92345-8. View

Carson D, Kaye J, Seegmiller J . Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977; 74(12):5677-81. PMC: 431856. DOI: 10.1073/pnas.74.12.5677. View

10.

Coleman M, DOnofrio J, HUTTON J, HAHN L, Daoud A, Lampkin B . Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem. 1978; 253(5):1619-26. View

11.

Cohen A, Hirschhorn R, Horowitz S, Rubinstein A, POLMAR S, Hong R . Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978; 75(1):472-6. PMC: 411272. DOI: 10.1073/pnas.75.1.472. View

12.

Carson D, Kaye J, Seegmiller J . Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J Immunol. 1978; 121(5):1726-31. View

13.

Mitchell B, Mejias E, Daddona P, Kelley W . Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978; 75(10):5011-4. PMC: 336252. DOI: 10.1073/pnas.75.10.5011. View

14.

Koller C, Mitchell B, Grever M, Mejias E, Malspeis L, METZ E . Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition. Cancer Treat Rep. 1979; 63(11-12):1949-52. View

15.

Dow L, Bell D, Poulakos L, Fridland A . Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res. 1980; 40(5):1405-10. View

16.

Plunkett W, Chubb S, Alexander L, Montgomery J . Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 1980; 40(7):2349-55. View

17.

Prentice H, Smyth J, Ganeshaguru K, Wonke B, Bradstock K, Janossy G . Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet. 1980; 2(8187):170-2. DOI: 10.1016/s0140-6736(80)90060-4. View

18.

Mitchell B, Koller C, Heyn R . Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. Blood. 1980; 56(3):556-9. View

19.

BROCKMAN R, Cheng Y, SCHABEL Jr F, Montgomery J . Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res. 1980; 40(10):3610-5. View

20.

Siaw M, Mitchell B, Koller C, Coleman M, HUTTON J . ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A. 1980; 77(10):6157-61. PMC: 350233. DOI: 10.1073/pnas.77.10.6157. View